Trial · NCT07289997
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
NCT07289997, Phase 2, Recruiting, Hebei Medical University Fourth Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC). Trials, record NCT07289997. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07289997
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
- NCT number
- NCT07289997
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 39 participants, estimated
- Lead sponsor
- Hebei Medical University Fourth Hospital
- Conditions
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
- Interventions
- Iparomlimab and Tuvonralimab Injection (QL1706)
- First posted
- 2025-12-17
- Last updated
- 2025-12-17
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | 24months | The objective response rate (ORR), which is the proportion of patients with complete response and partial response as assessed according to the RECIST1.1 criteria |
| Secondary | Progression-free survival (PFS) | 36month | The period from the start of treatment to disease progression, death from any cause, or the end of follow-up, whichever occurs first |
| Secondary | Overall survival (OS) | 48months | The time from the start of treatment to death due to any cause or the end of follow-up |
| Secondary | Disease control rate (DCR) | 24months | Disease control rate (DCR) : It refers to the proportion of patients who achieved PR、CR and SD after treatment. DCR=CR+PR+SD |
| Secondary | Adverse Events（AEs） | 36months | Incidence of adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07289997
GET https://conductscience.org/api/trials/v1/NCT07289997/registered